Tuberculosis Therapy: Smallest Particles Will Deliver the Drug to the ... - Newswise

Newswise — Tuberculosis is the infectious disease with the highest death rate worldwide. As reported by WHO, therapy-resistant tuberculosis infections are increasing. Diseases due to this bacterial infection may also occur in Germany. Tuberculosis represents a special challenge for two reasons: First, the bacteria encapsulate in tissue, mostly in the lungs, where they may be inactive for years and cause symptoms long after the primary infection. Second, tuberculosis bacteria often are resistant against two or more common antibiotics. Increasing occurrence of therapy-resistant strains is caused by insufficient drug concentrations at the place of infection and a premature termination of the treatment due to the often severe side effects of the antibiotics. 

A nanomedical approach can help to reduce the development of further resistances. Nanoparticles will be used to carry new antibiotics directly to the source of infection and infected cells. In this way, drug concentration may be increased locally in the lungs. "However, newly developed antibiotics often are lipophilic and fat-soluble and cannot or can hardly be administered in water. They can hardly be absorbed when contained in the stomach, blood, or cell fluid," explains Professor Claus Feldmann, Head of a research group at KIT's Institute for Inorganic Chemistry (AOC).

Presently, patients suffering from tuberculosis are treated with high doses over a long time in order to have the pathogens reached in the foci of infection. The partly severe side effects, such as liver damage, often cause terminations of the therapy, as a result of which further resistances develop. In future, nanoparticles will be used for the specific delivery of antibiotics. "We have already tested several nanocarriers for transporting antibiotics to the tuberculosis pathogens in mice. The new nanocarriers developed by our colleagues at KIT now convinced me that it is possible to directly deliver high doses of antibiotics to the foci of tuberculosis in the lungs without affecting other organs," says Professor Ulrich E. Schaible, Head of the Cellular Microbiology Group and Director of the Research Center Borstel, Leibniz Lung Center.  

KIT-developed Particles Contain Very High Drug Concentrations 

Researchers at KIT's Institute for Inorganic Chemistry have succeeded in producing nanoparticles with extremely high concentrations of antibiotics. "Concentration of the antibiotic is up to 99% of the total weight of the particles," Feldmann says. "According to literature, a maximum of 10% only has been usually reached so far." The KIT-made nanocarriers can be dispersed in water. When inhaled, the aerosol enters the depth of the lungs. At the Research Center Borstel, researchers under the direction of tuberculosis expert Schaible, in cooperation with other partners from Germany, Austria, and Belgium, tested the effectiveness of the nanoparticles with good results in both the lab and the living organism. Work was carried out within the ANTI-TB project funded by the Federal Ministry of Education and Research (BMBF). The researchers report in ACS Nano that is issued by the American Chemical Society (ACS). Meanwhile, KIT and the Research Center Borstel have applied for a joint patent. "Still, a lot of work will be needed until this aerosol formulation can be applied to humans," Schaible says. 

Nanocarriers Overcome Biological Barriers

The amorphous nanoparticles for inhalation contain a Bedaquilin concentration of 69% or a BTZ-043 concentration of 99%. Both antibiotics are effective against multi-resistant tuberculosis bacteria. Surfactants make the highly lipophilic antibiotics disperse in water. Dispersions with 4.0 mg of Bedaquilin / ml or 4.2 mg BTZ-043 / ml remain stable for several weeks. When tested in mice, the effectiveness of nanoparticle dispersions exceeded that of conventional BTZ-043 solutions for pulmonary inhalation by 50%. The nanocarriers proved to be capable of overcoming various biological barriers. High concentrations were measured in the lungs, but not in the liver and spleen. 

Original Publication
David Rudolph, Natalja Redinger, Katharina Schwarz, Feng Li, Gabriela Hädrich, Michaela Cohrs, Lea Ann Dailey, Ulrich E. Schaible, and Claus Feldmann: Amorphous Drug Nanoparticles for Inhalation Therapy of Multidrug-Resistant Tuberculosis. 
ACS Nano, 2023. DOI: 10.1021/acsnano.3c01664 

About the Research Center Borstel, Leibniz Lung Center (FZB):

The Research Center Borstel is the Lung Research Center of the Leibniz Association. Its work focuses on chronic inflammatory diseases of the lung, such as asthma, chronic obstructive pulmonary disease (COPD), and allergies, as well as on infectious inflammations of the lung, such as tuberculosis. The paramount goal of FZB's interdisciplinary research is to elucidate the causes and mechanisms of chronic inflammatory and degenerative diseases of the lung in order to derive new innovative concepts for their diagnosis, prevention, and therapy.  

More Information

Being "The Research University in the Helmholtz Association", KIT creates and imparts knowledge for the society and the environment. It is the objective to make significant contributions to the global challenges in the fields of energy, mobility, and information. For this, about 9,800 employees cooperate in a broad range of disciplines in natural sciences, engineering sciences, economics, and the humanities and social sciences. KIT prepares its 22,300 students for responsible tasks in society, industry, and science by offering research-based study programs. Innovation efforts at KIT build a bridge between important scientific findings and their application for the benefit of society, economic prosperity, and the preservation of our natural basis of life. KIT is one of the German universities of excellence.

Adblock test (Why?)